As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
How Do Ozempic (Semaglutide GLP-1) Injections Support Medical Weight Loss Beyond Appetite Control
This Mismatch in Timing Can Stop the Digestive System From Processing Food Appropriately
The Public Health Agency of Canada reported that around 3.9 million people in Canada over the age of one were living with diagnosed diabetes, representing 9.7% of the population
Internal hemorrhoids also may protrude (prolapse) outside the anus, where they appear as small, grape-like masses
More research is needed to understand this fully